Lucid Diagnostics Reports Revenue Growth and Secures Funding

3 days ago · Lucid Diagnostics ( (LUCD)) has provided an update. Lucid Diagnostics reported a 20% increase in revenue for its EsoGuard esophageal DNA test in the third quarter of 2024, …

CouponFollow Extension

20%
OFF

Lucid Diagnostics Reports Revenue Growth And Secures Funding

1 week from now

3 days ago · Lucid Diagnostics ( (LUCD)) has provided an update. Lucid Diagnostics reported a 20% increase in revenue for its EsoGuard esophageal DNA test in the third quarter of 2024, …

nasdaq.com

20%
OFF

Earnings Call: Lucid Diagnostics Reports Revenue Growth And …

1 week from now

2 days ago · The company's reported 20% sequential revenue growth to $1.2 million in Q3 2024 is consistent with InvestingPro data showing a remarkable revenue growth of 379.19% over …

investing.com

50%
OFF

Lucid Diagnostics' EsoGuard Revenue Surges 50% YoY, Sets …

1 week from now

2 days ago · Lucid Diagnostics reported Q3 2024 financial results with EsoGuard® revenue of $1.2M, showing a 20% sequential increase from Q2 and 50% annual growth.The company …

stocktitan.net

84%
OFF

Lucid Diagnostics Revenue 2018-2024 - Stock Analysis

1 week from now

Oct 29, 2024 · Lucid Diagnostics had revenue of $976.00K in the quarter ending June 30, 2024, with 513.84% growth. This brings the company's revenue in the last twelve months to $3.80M, …

stockanalysis.com

$0.82
OFF

Lucid Diagnostics (LUCD) Stock Price, News & Analysis - MarketBeat

1 week from now

1 day ago · Earnings Growth. Earnings for Lucid Diagnostics are expected to grow in the coming year, from ($0.82) to ($0.62) per share. Price to Earnings Ratio vs. the Market. ... Lucid …

marketbeat.com

FAQs about Lucid Diagnostics Reports Revenue Growth and Secures Funding Coupon?

What is lucid Diagnostics Inc (lucd)?

Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (Nasdaq: PAVM, PAVMZ) ( "PAVmed"), today provided a business update for the Company and presented financial results for the three months ended June 30, 2024. ...

How do I call lucid diagnostics business update?

Alternatively, to access the conference call by telephone, U.S.-based callers should dial 1-800-836-8184 and international listeners should dial 1-646-357-8785. All listeners should provide the operator with the conference call name "Lucid Diagnostics Business Update" to join. ...

How did lucid diagnostics perform in the third quarter?

The company reported a significant year-over-year revenue growth in the third quarter, driven by increased average selling prices and volume growth. Additionally, Lucid Diagnostics has shown potential for future expansion by tapping into concierge medicine, aiming to enhance its direct-pay revenue stream. ...

Who owns the stock of Lucid Diagnostics?

Lucid Diagnostics' stock is owned by many different institutional and retail investors, with LPL Financial LLC owning 0.07%. To buy shares of Lucid Diagnostics, you can use any online brokerage account. ...

Should you buy lucid diagnostics (lucd)?

In a report released yesterday, Anthony Vendetti from Maxim Group reiterated a Buy rating on Lucid Diagnostics (LUCD – Research Report), with a price target of $4.00. Anthony Vendetti has given his Buy rating due to a combination of factors related to Lucid Diagnostics’ recent performance and strategic progress. ...

Does Lucid Diagnostics pay a dividend?

Lucid Diagnostics does not currently pay a dividend. Short interest in Lucid Diagnostics has recently increased by 9.57%, indicating that investor sentiment is decreasing significantly. The short interest ratio is 2.7, which is generally considered an acceptable ratio of short interest to trading volume. ...